Regado files, GW prices as IPOs build steam
This article was originally published in Scrip
Executive Summary
The market for biotechnology initial public offerings continues to heat up with Regado Biosciences seeking up to $75 million from an IPO to support Phase III development of its anticoagulant REG1 and GW Pharmaceuticals launching an IPO on 1 May to enter the US public markets.